Acquired angioedema in British Columbia: a province-wide collaborative case series
Abstract Background Acquired angioedema (AAE) is a rare condition characterized by recurrent episodes of bradykinin-mediated soft tissue edema. It is thought to occur secondary to dysfunction of the C1-esterase inhibitor (C1-INH) regulatory protein, most commonly in association with an underlying hematologic disorder. The present study describes a cohort of AAE patients across the province of British Columbia. Methods This was a retrospective case series conducted in collaboration with four Allergy and Immunology clinics in British Columbia. Patients were included if they had a formal diagnosis of AAE, had no family history suggestive of HAE, and a biochemical profile in keeping with AAE, namely low C1-INH functional activity and low C4. Data gathered included epidemiologic profile, inciting event, presenting symptoms, frequency and severity of attacks, and response to acute and chronic treatments. Results Eight patients met study inclusion criteria; median age at diagnosis/presentation was 59. All eight (8/8) were diagnosed with hematologic disorders. For five patients (5/8), AAE was what prompted their hematologic evaluation. All eight patients (8/8) experienced abdominal swells as part of their presenting symptoms, and six of the eight (6/8) experienced facial, oropharyngeal or upper airway swelling. Five patients (5/8) were treated acutely with IV C1-INH replacement, four of whom (4/5) responded. All three patients (3/8) who received icatibant acutely experienced significant improvement or complete resolution of symptoms. Responses to long-term prophylaxis were more heterogeneous, though patients who received curative treatment for their underlying hematologic malignancy uniformly achieved complete or near-complete remission. One patient with CLL achieved complete remission of AAE symptoms with lanadelumab. Conclusions This Canadian cohort highlights the strong association between AAE and hematologic disorders, with AAE being the impetus for hematologic workup in many of the included patients. With the high frequency of abdominal swelling in our cohort, while AAE is rare, we propose it be considered on the differential for patients with suspected hematologic disorder experiencing new abdominal symptoms of unclear etiology. Our cohort suggests that historic treatments like C1-INH replacement and danazol may still produce good treatment effect, though newer agents like icatibant and lanadelumab similarly demonstrated excellent treatment responses.
Authors
- Amin S. Kanani (ORCID: https://orcid.org/0000-0002-2081-9318)
- Manstein Kan
- Amanda Jagdis
- Julia A. Cahill (ORCID: https://orcid.org/0000-0002-7443-9193)
- Asha Bansal
- Nicole Weir
- Hien Reeves
Institutions
- University of British Columbia (CA)
- University of Alberta (CA)
- University of Saskatchewan (CA)
Publication Details
- Journal
- Allergy Asthma and Clinical Immunology
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1186/s13223-026-01082-6
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00